Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6000329

CCC(c1ccncc1)c1ccc(F)c(F)c1.N

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.58
DPP4 P27487 2/20 0.41
AKR1C3 P42330 2/20 0.39
AKR1C2 P52895 2/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
PDE4A P27815 3/20 0.38
S1PR1 P21453 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
DPP8 Q6V1X1 1/20 0.35
CYP19A1 P11511 1/20 0.35
SHBG P04278 1/20 0.35
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
PDPK1 O15530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL5999953 0.82 CYP17A1 (0.56) CYP17A1PDE4AS1PR1SLC6A2SLC6A4
Ammonia Solution, Strong SCHEMBL5998637 0.81 CYP51A1 (0.45) CYP17A1AKR1C3AKR1C2SLC6A2SLC6A4
SCHEMBL377276 0.80 CYP17A1 (0.63) CYP17A1S1PR1SLC6A2SLC6A4SLC6A3
Ammonia Solution, Strong SCHEMBL5999961 0.79 CYP17A1 (0.54) CYP17A1DPP4CYP11B1PDE4AS1PR1
Ammonia Solution, Strong SCHEMBL5999692 0.79 CYP19A1 (0.59) CYP17A1PDE4ASLC6A2SLC6A4SLC6A3
Ammonia Solution, Strong SCHEMBL6000241 0.79 CYP17A1 (0.51) CYP17A1CYP11B1CYP11B2PDE4AS1PR1
Ammonia Solution, Strong SCHEMBL5999466 0.77 AKR1C3 (0.42) CYP17A1DPP4AKR1C3AKR1C2CYP11B1
Ammonia Solution, Strong SCHEMBL5999950 0.77 CYP17A1 (0.57) CYP17A1S1PR1SLC6A2SLC6A4SLC6A3
Ammonia Solution, Strong SCHEMBL5999595 0.77 SLC6A4 (0.50) CYP17A1PDE4AS1PR1SLC6A2SLC6A4
Ammonia Solution, Strong SCHEMBL5999712 0.76 SLC6A3 (0.59) CYP17A1S1PR1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CYP17A1 4384/4885DPP4 2205/4885AKR1C3 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.